mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model

References

• Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: Progress and future prospects. JNCI J Natl Cancer Inst 2014; 106:djt435; PMID:24511108; http://dx.doi.org/10.1093/jnci/djt435
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383:816-27; PMID:2405-4424; http://dx.doi.org/10.1016/S0140-6736(13)60802-8
   PubMed Web of Science ®Google Scholar
• Gogas H, Polyzos A, Kirkwood J. Immunotherapy for advanced melanoma: Fulfilling the promise. Cancer Treat Rev 2013; 39:879-85; PMID:23725878; http://dx.doi.org/10.1016/j.ctrv.2013.04.006
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long G V, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Hodi FS1, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   Google Scholar
• Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 2003; 22:3180-7; PMID:12789294; http://dx.doi.org/10.1038/sj.onc.1206462
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Corthals J, Van Nuffel AMT, Benteyn D, Heirman C, Bonehill A, Thielemans K, Neyns B. Long-term clinical outcome of melanoma patients treated with messenger RNA electroporated dendritic cell therapy following complete resection of macrometastases. Cancer Immunol Immunother 2015; 64:381-8; PMID:25548092; http://dx.doi.org/10.1007/s00262-014-1642-8
   PubMed Web of Science ®Google Scholar
• Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30:1-22; PMID:22136168; http://dx.doi.org/10.1146/annurev-immunol-100311-102839
   PubMed Web of Science ®Google Scholar
• Mac Keon S, Ruiz MS, Gazzaniga S, Wainstok R. Dendritic cell-based vaccination in cancer: Therapeutic implications emerging from murine models. Front Immunol 2015; 6:1-18; PMID:25657648; http://dx.doi.org/10.3389/fimmu.2015.00243
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
   PubMed Web of Science ®Google Scholar
• Gallois A, Bhardwaj N. Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. Front Immunol 2013; 4:1-8; PMID:23355837; http://dx.doi.org/10.3389/fimmu.2013.00436
   PubMed Web of Science ®Google Scholar
• Lutz MB, Rößner S. Factors influencing the generation of murine dendritic cells from bone marrow: The special role of fetal calf serum. Immunobiology 2008; 212:855-62; PMID:18086384; http://dx.doi.org/10.1016/j.imbio.2007.09.001
   Web of Science ®Google Scholar
• Umansky V, Sevko A, Gebhardt C, Utikal J. Myeloid-derived suppressor cells in malignant melanoma. J Dtsch Dermatologische Gesellschaft 2014; 12:1021-7; PMID:25263083; http://dx.doi.org/10.1111/ddg.12411
   PubMed Web of Science ®Google Scholar
• Umansky V, Sevko A. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22:319-26; PMID:22349515; http://dx.doi.org/10.1016/j.semcancer.2012.02.003
   PubMed Web of Science ®Google Scholar
• Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012; 144:250-68; PMID:22858650; http://dx.doi.org/10.1016/j.clim.2012.06.003
   PubMed Web of Science ®Google Scholar
• Facciabene A, Motz GT, Coukos G. T-regulatory cells: Key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72:2162-71; PMID:22549946; http://dx.doi.org/10.1158/0008-5472.CAN-11-3687
   PubMed Web of Science ®Google Scholar
• Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol 2013; 34:33-40; PMID:22999714; http://dx.doi.org/10.1016/j.it.2012.08.005
   PubMed Web of Science ®Google Scholar
• Cafri G, Amram E, Rinott G, Koifman G, Fishman S, Keisari Y, Tzehoval E, Margalit A, Eisenbach L, Gross G. Coupling presentation of MHC class I peptides to constitutive activation of antigen-presenting cells through the product of a single gene. Int Immunol 2011; 23:453-61; PMID:21652516; http://dx.doi.org/10.1093/intimm/dxr033
   PubMed Web of Science ®Google Scholar
• Cafri G, Sharbi-Yunger A, Tzehoval E, Alteber Z, Gross T, Vadai E, Margalit A, Gross G, Eisenbach L. mRNA-transfected dendritic cells expressing polypeptides which link MHC-I presentation to constitutive TLR4 activation confer tumor immunity. Mol Ther 2015; 23(8):1391-400; PMID:25997427; http://dx.doi.org/10.1038/mt.2015.90
   PubMed Web of Science ®Google Scholar
• Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I. Transgenic mouse model for skin malignant melanoma. Oncogene 1998; 17:1885-8; PMID:9778055; http://dx.doi.org/10.1038/sj.onc.1202077
   PubMed Web of Science ®Google Scholar
• Umansky V, Abschuetz O, Osen W, Ramacher M, Zhao F, Kato M, Schadendorf D. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res 2008; 68:9451-8; PMID:19010920; http://dx.doi.org/10.1158/0008-5472.CAN-08-1464
   PubMed Web of Science ®Google Scholar
• Abschuetz O, Osen W, Frank K, Kato M, Schadendorf D, Umansky V. T-cell mediated immune responses induced in ret transgenic mouse model of malignant melanoma. Cancers (Basel) 2012; 4:490-503; PMID:24213320; http://dx.doi.org/10.3390/cancers4020490
   PubMedGoogle Scholar
• Lutz MB, Kukutsch N, Ogilvie a L, Rössner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223:77-92; PMID:10037236; http://dx.doi.org/10.1016/S0022-1759(98)00204-X
   PubMed Web of Science ®Google Scholar
• Henao-Tamayo MI, Ordway DJ, Irwin SM, Shang S, Shanley C, Orme IM. Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with mycobacterium tuberculosis. Clin Vaccine Immunol 2010; 17:618-25; PMID:20107011; http://dx.doi.org/10.1128/CVI.00368-09
   PubMed Web of Science ®Google Scholar
• Kim H, Cantor H. CD4 T-cell subsets and tumor immunity: The helpful and the not-so-helpful. Cancer Immunol Res 2014; 2:91-8; PMID:24778273; http://dx.doi.org/10.1158/2326-6066.CIR-13-0216
   PubMed Web of Science ®Google Scholar
• Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57:503-12; PMID:2785856; http://dx.doi.org/10.1016/0092-8674(89)90925-2
   PubMed Web of Science ®Google Scholar
• Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002; 196:619-28; PMID:12208877; http://dx.doi.org/10.1084/jem.20012142
   PubMed Web of Science ®Google Scholar
• Grant CR, Liberal R, Mieli-Vergani G, Vergani D, Longhi MS. Regulatory T-cells in autoimmune diseases: Challenges, controversies and—yet—unanswered questions. Autoimmun Rev 2015; 14:105-16; PMID:25449680; http://dx.doi.org/10.1016/j.autrev.2014.10.012
   PubMed Web of Science ®Google Scholar
• Jethwa H, Adami AA, Maher J. Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: Is now the right time? Clin Immunol 2014; 150:51-63; PMID:24333533; http://dx.doi.org/10.1016/j.clim.2013.11.004
   PubMed Web of Science ®Google Scholar
• Zhang X, Kelaria S, Kerstetter J, Wang J. The functional and prognostic implications of regulatory T cells in colorectal carcinoma. J Gastrointest Oncol 2015; 10:307-13; PMID:26029458; http://dx.doi.org/10.3978/j.issn.2078-6891.2015.017
   Google Scholar
• Katoh H, Watanabe M. Myeloid-derived suppressor cells and therapeutic strategies in cancer. J Mediat Inflamm 2015; 2015:1-12; PMID:26078490; http://dx.doi.org/10.1155/2015/159269
   Web of Science ®Google Scholar
• Draghiciu O, Lubbers J, Nijman HW, Daemen T. Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology 2015; 4:e954829; PMID:25949858; http://dx.doi.org/10.4161/21624011.2014.954829
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived-supressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Cauley LS, Miller EE, Yen M, Swain SL. Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-gamma. J Immunol 2000; 165:6056-66; PMID:11086037; http://dx.doi.org/10.4049/jimmunol.165.11.6056
   PubMed Web of Science ®Google Scholar
• Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol 1998; 161:5313-20; PMID:9820504
   PubMed Web of Science ®Google Scholar
• Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking IFN tumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci 2011; 108:17111-6; PMID:21969559; http://dx.doi.org/10.1073/pnas.1108121108
   PubMed Web of Science ®Google Scholar
• Lengagne R, Pommier A, Caron J, Douguet L, Garcette M, Kato M, Avril MF, Abastado JP, Bercovici N, Lucas B, et al. T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma. PLoS One 2011; 6:1-10; PMID:21633700; http://dx.doi.org/10.1371/journal.pone.0020235
   Web of Science ®Google Scholar